Abstract

Pregnant women are usually at risk of urinary tract infections (UTIs) such as asymptomatic bacteriuria. In the current multidrug-resistance era, appropriate diagnosis and treatment should be provided to avoid complications in pregnant women in developing countries, which have limited facilities, such as Indonesia. The aim of this study was to evaluate in vitro susceptibility tests. Urinary isolates were collected from 715 pregnant women who visited eight Community Health Centers in Jakarta, Indonesia, between 2015 and 2017. We identified bacterial uropathogens from samples that were positive for nitrite/leukocyte esterase (LE), using two types of VITEK cards. Since noncompliance among patients is a major problem, fosfomycin-trometamol 3 g single-dose sachets were given to the patients, and the side effects of the medication and neonatal outcomes were reported. Asymptomatic bacteriuria was found in 10.5% of the 715 pregnant women. Escherichia coli was the most common etiological factor (26.7%), followed by Klebsiella pneumoniae (20%), Streptococcus agalactiae (9.3%), Enterobacter cloacae (5.3%), Enterococcus faecalis (5.3%), Staphylococcus saprophyticus (4%), Acinetobacter baumannii (4%), and others. Out of 76 pregnant women who took fosfomycin-trometamol, two complained of diarrhea that subsided without medication and fever that responded to paracetamol. Neonatal outcomes showed 100% full-term and normal-weight babies. E. coli, including extended-spectrum beta-lactamase- (ESBL-) producing E. coli, was 100% susceptible to fosfomycin. Nitrite/LE test results are often used as evidence for empiric antibiotic administration for treating asymptomatic bacteriuria in pregnancy, but the diagnosis should be confirmed using culture tests. Based on in vitro susceptibility patterns and medication outcomes, fosfomycin-trometamol single dose could be administered to noncompliant UTI patients, including pregnant women.

Highlights

  • Pregnant women form a part of the group at risk of urinary tract infections (UTIs)

  • Out of the 76 pregnant women who took the fosfomycin-trometamol 3 g single-dose sachet, two women complained of side effects consisting of diarrhea that subsided without medication and fever that responded to paracetamol, respectively

  • This study clearly demonstrates the urgent need for periodic surveys to determine the susceptibility patterns of microorganisms that cause asymptomatic bacteriuria in pregnant women

Read more

Summary

Introduction

Pregnant women form a part of the group at risk of urinary tract infections (UTIs). The prevalence of UTIs in pregnant women is approximately 2%–10% [1, 2]. Their reduced immunity appears to encourage the growth of both commensal and noncommensal microorganisms. UTI in pregnant women is frequently manifested as asymptomatic bacteriuria [2,3,4]. Asymptomatic bacteriuria in pregnancy poses a significant risk because untreated cases have a high likelihood (up to 40%) of progressing to acute pyelonephritis that can cause morbidity and even death of the mother and fetus [3]. The choice of therapy is generally based on common pathogens encountered, susceptibility patterns, evidence, clinician consensus, antimicrobial stewardship principles, formulary availability, and antimicrobial costs [7, 8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call